Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis. Ebglyss showed sustained similar levels of skin clearance when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback